Skip to main content
Unknown status

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

By April 24, 2017No Comments

Condition

Mesothelioma

Estimated Enrollment: 56

Age Group: 18 Years to 75 Years   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: GIMe/01/06

Study First Received: October 29, 2007

Last Updated: October 29, 2007

Estimated Primary Completion Date: null

 

Primary Outcome Measures:

Overall response rate|Progression-free-survival; Overall Survival; Safety

Sponsors and Collaborators:

Gruppo Italiano MEsotelioma

Website Link: https://ClinicalTrials.gov/show/NCT00551252

Leave a Reply